EUVIMEDEUVIMED entdecken
Crossref

ROCK2 increases drug resistance in acute myeloid leukemia via metabolic reprogramming and MAPK/PI3K/AKT signaling

Muxia Yan, Xin Luo, Hong Han, Jiachun Qiu, Qian Ye, Li Zhang, Yiqian Wang

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112897 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Muxia Yan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Drug Resistance, Neoplasm, rho-Associated Kinases, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guilin Medical University, Guangzhou Municipal Science and Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rho-associated coiled-coil kinase 2 (ROCK2) is classified as a member of the serine/threonine protein kinase family and has been identified as a key driver of the development of various forms of cancer. The cause of ROCK2's impact on acute myeloid leukemia (AML) is still unknown. We found that ROCK2 expression was higher in AML patients, leading to lower complete response rates and worse overall survival. Additionally, ROCK2 expression was elevated in the doxorubicin-resistant leukemia cell line HL-60/ADM when compared to their individual parent cells. Moreover, the suppression or inhibition of ROCK2 leads to enhanced drug sensitivity in both AML cell lines and primary AML specimens, along with a notable decrease in downstream signaling pathways. Furthermore, the suppression of ROCK2 caused disruption of cellular energy production pathways by directly affecting the functionality of proteins within the mitochondrial electron transport chain. Finally, we discovered that TRIM26, a specific E3 ligase, is capable of ubiquitylating ROCK2, and the upregulation of TRIM26 within HL-60/ADM cells resulted in heightened sensitivity to the drug and reduced resistance. Thus, our study presents a new strategy for overcoming drug resistance in AML through targeting ROCK2/AKT/MAPK signaling pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteDrug Resistance, Neoplasmrho-Associated KinasesProto-Oncogene Proteins c-aktSignal TransductionHumansHL-60 CellsPhosphatidylinositol 3-KinasesMaleFemaleDoxorubicinCell Line, TumorMiddle AgedAdultMetabolic Reprogramming

Stichwörter der Autor:innen

Acute myeloid leukemiaDrug resistanceMetabolic reprogrammingROCK2

Substanzen

rho-Associated KinasesROCK2 protein, humanProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesDoxorubicin

Autor:innen und Institutionen

  • Department of Hematology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
  • GMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, China.
  • Department of Hematology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China. Electronic address: gzxys@sina.cn.
  • GMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, China. Electronic address: yiqian.wang@gzhmu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Guilin Medical University
  • Guangzhou Municipal Science and Technology Project
  • Guangdong Medical Research Foundation

Zitieren

APA

Yan, M., Luo, X., Han, H., Qiu, J., Ye, Q., Zhang, L., & Wang, Y. (2024). ROCK2 increases drug resistance in acute myeloid leukemia via metabolic reprogramming and MAPK/PI3K/AKT signaling. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112897

Vancouver

Yan M, Luo X, Han H, Qiu J, Ye Q, Zhang L, et al. ROCK2 increases drug resistance in acute myeloid leukemia via metabolic reprogramming and MAPK/PI3K/AKT signaling. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112897

BibTeX
@article{Yan2024,
  author = {Yan, Muxia and Luo, Xin and Han, Hong and Qiu, Jiachun and Ye, Qian and Zhang, Li and Wang, Yiqian},
  title = {ROCK2 increases drug resistance in acute myeloid leukemia via metabolic reprogramming and MAPK/PI3K/AKT signaling},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112897}
}
Kostenlos starten →